

### HALLUX FOCUS AND MISSION

- Hallux is a clinical-stage pharmaceutical company focused on developing the first subungual topical prescription drug product for treating chronic onychomycosis (toenail fungus).
- To date, treatments for toenail fungus have been either low cure rate topical products that must be applied daily for 12 months or oral products taken daily for three months that can cause systemic side effects.
- Our mission is to provide a novel topical solution for patients with chronic onychomycosis that results in a high cure rate without the risk of systemic side effects.


### HALLUX ONYCHOMYCOSIS SOLUTION

#### *The Only Local, Direct to the Nail Bed Approach to treating Toenail Fungus*

- Our treatment goal is focused on safely treating onychomycosis with a topical subungual dosage form that is highly effective, without the systemic safety issues associated with oral medications.
- Our innovative subungual treatment approach delivers high concentrations of terbinafine, a proven fungicidal (fungus-killing) drug, directly to the nail bed site of the infection.
- Delivering this proven fungicidal drug to the nail bed enables high concentrations of terbinafine to reach the site of infection where it is needed instead of introducing it systemically where it can affect the liver and interact with other drugs the patients may be taking.
- The Hallux subungual topical is administered straight to the site of infection creating a depot of fungicidal drug well above the MFCs (minimum fungicidal concentrations) that eradicates disease causing fungal invaders enabling the growth of new disease free nail and ultimate complete cure of onychomycosis.

#### *Without the Risks Associated with Oral Medication*

- At Hallux, our approach to treating onychomycosis is to safely deliver high concentrations of the powerful, fungus-killing drug directly to the nail bed.
- In this way, we kill the fungus at the infection site without exposing the body and vital organ systems to systemic medications.
- Our approach to treating onychomycosis directly and locally in the toenail bed eliminates the:
  - Need for daily oral medications
  - Risk of liver toxicity associated with oral medications
  - Potential for systemic side effects
  - Potential for harmful interactions with other systemic drugs
  - Need for brush on topicals that must be applied daily for twelve months or more



Hallux's subungual technology enables direct administration of terbinafine to the site of the infection resulting in high drug concentrations throughout the mycotic tissue in the nail bed and plate..

---

## DEVELOPMENT PATHWAY

- A Phase 2A 48-week clinical trial for the Company's first subungual dosage form HTS-519 completed in September 2018.
- This encouraging subungual pilot study enrolled 30 moderate to severe onychomycosis patients from a high volume podiatric clinic in the greater Phoenix, AZ area.

## MANAGEMENT AND BOARD

- The Leadership team at Hallux consists of experienced operators in pharmaceutical development and commercialization.
- The team includes:
  - Mark Taylor - Chief Executive Officer, Co-Founder/Board Member, Stockholder
  - Robert Orr - Board Member, Formulation Development/CMC, Stockholder
  - Christopher Agee - Drug Product Analytical Development, Stockholder
  - Jay Birnbaum, PhD - Board Member, Co-Founder, Clinical Advisor, Stockholder
  - Fred Reno PhD - Toxicology Advisor
  - Chris Dax - Clinical and Commercial Planning
  - Jeff Cole - Finance and Administration
  - Margie Mohler - Bioanalytical
  - Feng-Yu Lee - QA and Compliance
  - William P. Forbes - Board Member
  - Peter Steelman - Board Member

### FOR MORE INFORMATION:

Mark Taylor, CEO  
Hallux, Inc.  
949.637.4656  
[mark@halluxinc.com](mailto:mark@halluxinc.com)

